The city of Clearwater, Florida, currently has 7 active clinical trials seeking participants for Asthma research studies.
Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)
NCT03373045
Recruiting
The CHRONICLE Study is a multi-center, non-interventional, prospective cohort study of adults with severe asthma who do not achieve control with high-dose inhaled corticosteroid (ICS) therapy with additional controllers and/or require systemic corticosteroid or monoclonal antibody therapy. Data will be collected from the healthcare provider in a uniform manner for every patient enrolled using an electronic case report form (eCRF). Data will be collected monthly from patients via web-based survey... Read More
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
06/20/2024
Locations: Research Site, Clearwater, Florida
Conditions: Asthma
Register for Updates
Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma
NCT05251259
Recruiting
This is a randomised, placebo-controlled, double-blind study to assess the efficacy and safety of Atuliflapon administered once daily over a 12-week treatment period to adult participants with moderate to severe uncontrolled asthma.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/12/2024
Locations: Research Site, Clearwater, Florida
Conditions: Asthma
Register for Updates
A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma
NCT06376045
Recruiting
The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/12/2024
Locations: St Francis Medical Institute, Clearwater, Florida
Conditions: Asthma
Register for Updates
A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants 12 Years of Age and Older With Asthma
NCT06261957
Recruiting
The goal of this study is to assess and compare the safety and tolerability of salbutamol administered via metered dose inhaler (MDI) containing propellant 1,1-difluoroethane (HFA-152a) or 1,1,1,2-tetrafluoroethane (HFA-134a) in participants aged 12 years and above with asthma.
Gender:
All
Ages:
12 years and above
Trial Updated:
06/10/2024
Locations: GSK Investigational Site, Clearwater, Florida
Conditions: Asthma
Register for Updates
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)
NCT04609904
Recruiting
This is a variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care.
Gender:
All
Ages:
Between 12 years and 80 years
Trial Updated:
06/06/2024
Locations: Research Site, Clearwater, Florida +1 locations
Conditions: Asthma
Register for Updates
A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype
NCT04718389
Recruiting
This study will assess whether switching participants who have benefitted from mepolizumab or benralizumab to GSK3511294 (Depemokimab) is non-inferior to maintaining current treatment on the annualized rate of clinically significant exacerbations in participants with severe asthma with an eosinophilic phenotype. Throughout the study, all participants will continue their non-biologic Baseline standard of care (SoC) asthma treatment.
Gender:
All
Ages:
12 years and above
Trial Updated:
04/29/2024
Locations: GSK Investigational Site, Clearwater, Florida
Conditions: Asthma
Register for Updates
A Study of Patients With Chronic Disease
NCT04263727
Recruiting
TARGET-RWE is a 10-year, international, longitudinal, observational study of patients with chronic disease designed to specifically address important clinical questions that remain incompletely answered from registration trials. The protocol will follow a master protocol design in which a shared study infrastructure supports progressive development of the registry across the spectrum of chronic diseases.
Gender:
All
Ages:
All
Trial Updated:
08/24/2023
Locations: St. Francis Medical Institute, Clearwater, Florida
Conditions: Asthma, Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis, IPF, COPD, Respiratory Disease
Register for Updates